About danwei - Hangzhou DanWei Biotechnology Co. Ltd.

Company profile

Hangzhou Danwei Biotechnology Co., Ltd. is a holdi‍ng subsidiary of the listed company Zhejiang Orient Biotechnol↑ogy Co., Ltd. and is located in the Health Valley of Hangzhou Future Science and Tec™hnology City. Danwei integrates the research, development and production of in vitro diagnostic reagents and instruments globally, and is committed to providing faster, more ‍accurate and innovative solutions in the field of molecular diagnostics. I♥n addition to pursuing world-class standards in the field of in ✘vitro diagnostics and molecules, the company is actively deploying a‌ second-generation sequencing platform and striving to develop and innovate second-ge♦neration sequencing technologies. The core of Danwei's business is to serve people and enhance' global health by giving people insight into Danwei!

About COVID-19

In the earliest stage of the epidemic, Danwei reacted quickly and® the R&D team was on the front line, using advanced magneti★c bead technology to develop the SARS-CoV-2 extraction kit that can accurately extract nuΩcleic acid, and develope the SARS-CoV-2 detection kit, followed by the launch of the SARS-CoV-2 dir•ect detection kit that does not require amplificat≤ion extraction method. The SARS-CoV-2 direct detection kit, which guarantees the accuracy o<f test results while greatly shortening the detection time! Danwei has helped laboratories at home≠ and abroad to improve their SARS-CoV-2 detection cΩapability, provided diversified solutions for countries and regions around the world∞ to combat SARS-CoV-2, and strives to provide products that everyone t♦rusts and becomes a partner that everyone trusts.

Development History

2015

Hangzhou Danwei Biotechnology Co., Ltd. was established with a registered capital of 12¶.5 million RMB.
2017

Through the introduction of the project, move into the Future Technλology City Health Valley, the R&D laboratory was put into use, and 31 projects have currently being developed.
2018

The GMP production plant passed inspection and obtained the 1♣3485 system certificate
2019

The 6 first-class products being researched by company were registered and recorded in C¥hina Seven products of three categories were successfully registered in CE.
2020

During the epidemic, we dependently researched and developed the reagent kits used for t‍esting SARS-CoV-2, and assisted Orient Gene to successfully develop a nucleic acid detection kit §for the SARS-CoV-2, contributing to the prevention and control ☆of the epidemic.
2021

Obtained high-tech enterprise certificate
Succeeded in the three-level safety production standardization

Providing advanced, accurate and innovative diagnostic technology ↔to the world

Becoming the innovative brand leader among IVD manufac¶tures